Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey J Raizer

Showing results (61-70 of 79) with videos related to

Pageof 8
Sort By:
Neuro-Oncology|August 10, 2022
A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokineticsPriya U Kumthekar, Michael J Avram, Andrew B Lassman, et al.
Journal of Neuro-Oncology|June 30, 2009
Phase II trials of erlotinib or gefitinib in patients with recurrent meningiomaAndrew D Norden, Jeffrey J Raizer, Lauren E Abrey, et al.
Neuro-Oncology|January 10, 2015
Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic gliomaEudocia Q Lee, David A Reardon, David Schiff, et al.
Neuro-Oncology|February 13, 2010
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomasJeffrey J Raizer, Lauren E Abrey, Andrew B Lassman, et al.
Neuro-Oncology|February 13, 2010
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapyJeffrey J Raizer, Lauren E Abrey, Andrew B Lassman, et al.
Cancer|March 11, 2020
NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcomaEudocia Q Lee, Peixin Zhang, Patrick Y Wen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2022
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II StudyAndrew B Lassman, Juan Manuel Sepúlveda-Sánchez, Timothy F Cloughesy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01Andrew B Lassman, Michael R Rossi, Jeffrey J Raizer, et al.
Neurology|December 21, 2014
Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningiomaAndrew D Norden, Keith L Ligon, Samantha N Hammond, et al.
Neuro-Oncology|July 18, 2020
CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study designKurt A Jaeckle, Karla V Ballman, Martin van den Bent, et al.
Pageof 8

Showing results (61-70 of 79) with videos related to

Sort By:
Pageof 8
Neuro-Oncology|August 10, 2022
A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokineticsPriya U Kumthekar, Michael J Avram, Andrew B Lassman, et al.
Journal of Neuro-Oncology|June 30, 2009
Phase II trials of erlotinib or gefitinib in patients with recurrent meningiomaAndrew D Norden, Jeffrey J Raizer, Lauren E Abrey, et al.
Neuro-Oncology|January 10, 2015
Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic gliomaEudocia Q Lee, David A Reardon, David Schiff, et al.
Neuro-Oncology|February 13, 2010
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomasJeffrey J Raizer, Lauren E Abrey, Andrew B Lassman, et al.
Neuro-Oncology|February 13, 2010
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapyJeffrey J Raizer, Lauren E Abrey, Andrew B Lassman, et al.
Cancer|March 11, 2020
NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcomaEudocia Q Lee, Peixin Zhang, Patrick Y Wen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2022
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II StudyAndrew B Lassman, Juan Manuel Sepúlveda-Sánchez, Timothy F Cloughesy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01Andrew B Lassman, Michael R Rossi, Jeffrey J Raizer, et al.
Neurology|December 21, 2014
Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningiomaAndrew D Norden, Keith L Ligon, Samantha N Hammond, et al.
Neuro-Oncology|July 18, 2020
CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study designKurt A Jaeckle, Karla V Ballman, Martin van den Bent, et al.
Pageof 8